AbbVie Files SNDA For Atogepant For Label Expansion

AbbVie (ABBV) announced it has submitted a supplemental New Drug Application for atogepant to the FDA to support the preventive treatment of chronic migraine in adults. The company noted that the submission is based on pivotal phase 3 PROGRESS chronic migraine study evaluating atogepant in adult patients that met primary endpoint.

Michael Gold, therapeutic area head, neuroscience development, AbbVie, said: "This sNDA approval would also diversify AbbVie's migraine portfolio and make it the only company to offer two approved preventive treatments for those living with chronic migraine."

Atogepant is marketed as QULIPTATM in the U.S. and is approved to treat adults with episodic migraine.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Activity in the U.S. manufacturing sector slowed by more than expected in the month of September but still saw continued growth, according to a report released by the Institute for Supply Management on Monday. Stocks have moved sharply higher in morning trading on Monday, regaining ground following a dismal September. The major averages have all shown substantial moves to the upside. Swedish geneticist Svante Paabo has won this year's Nobel Prize in Physiology/Medicine for his discoveries concerning the genomes of extinct hominins and human evolution. Through his pioneering research, Svante Pääbo accomplished something seemingly impossible: sequencing the genome of the Neanderthal, an extinct relative of present-day humans. He also made the sensational discovery of a previous
Follow RTT